TARS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TARS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Tarsus Pharmaceuticals's Enterprise Value is $1,708.0 Mil. Tarsus Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-101.7 Mil. Therefore, Tarsus Pharmaceuticals's EV-to-FCF for today is -16.80.
The historical rank and industry rank for Tarsus Pharmaceuticals's EV-to-FCF or its related term are showing as below:
During the past 6 years, the highest EV-to-FCF of Tarsus Pharmaceuticals was 95.57. The lowest was -714.44. And the median was -5.41.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2024-12-13), Tarsus Pharmaceuticals's stock price is $52.50. Tarsus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-3.810. Therefore, Tarsus Pharmaceuticals's PE Ratio (TTM) for today is At Loss.
The historical data trend for Tarsus Pharmaceuticals's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsus Pharmaceuticals Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
EV-to-FCF | Get a 7-Day Free Trial | - | -31.15 | 93.55 | -3.94 | -4.03 |
Tarsus Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EV-to-FCF | Get a 7-Day Free Trial | -3.92 | -4.03 | -7.96 | -6.04 | -9.95 |
For the Biotechnology subindustry, Tarsus Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Tarsus Pharmaceuticals's EV-to-FCF falls into.
Tarsus Pharmaceuticals's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 1708.019 | / | -101.675 | |
= | -16.80 |
Tarsus Pharmaceuticals's current Enterprise Value is $1,708.0 Mil.
Tarsus Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-101.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsus Pharmaceuticals (NAS:TARS) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tarsus Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 52.50 | / | -3.810 | |
= | At Loss |
Tarsus Pharmaceuticals's share price for today is $52.50.
Tarsus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.810.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Tarsus Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Link William J Phd | director | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Jeffrey S Farrow | officer: See Remarks | TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
Dianne C. Whitfield | officer: Chief Human Resources Officer | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Bryan Wahl | officer: General Counsel | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Seshadri Neervannan | officer: Chief Operating Officer | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Bobak R. Azamian | director, 10 percent owner, officer: President and CEO | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Aziz Mottiwala | officer: Chief Commercial Officer | 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401 |
Jose M. Trevejo | officer: Chief Medical Officer | C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Andrew D. Goldberg | director | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Elizabeth Yeu Lin | director | 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630 |
Leonard M. Greenstein | officer: Chief Financial Officer | 24562 BELGREEN PLACE, LAKE FOREST CA 92630 |
Mark J. Holdbrook | officer: V.P., Clinical Affairs | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Scott W Morrison | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
Vivo Capital Fund Ix, L.p. | 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
Michael Ackermann | director, 10 percent owner | 202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540 |
From GuruFocus
By GuruFocus News • 11-14-2024
By GlobeNewswire • 08-28-2024
By Marketwired • 11-13-2024
By Marketwired • 07-29-2024
By GuruFocus News • 10-09-2024
By GuruFocus Research • 05-09-2024
By Marketwired • 09-25-2024
By GlobeNewswire • 09-25-2024
By GuruFocus Research • 02-28-2024
By GuruFocus Research • 02-27-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.